A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults

This publication has 43 references indexed in Scilit:

• Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
  Cell Metabolism, 2018
• Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
  JAMA Psychiatry, 2017
• GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
  Diabetologia, 2016
• Premature Mortality Among Adults With Schizophrenia in the United States
  JAMA Psychiatry, 2015
• The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
  International Journal of Clinical Pharmacy, 2015
• Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
  World Psychiatry, 2015
• Mortality in Mental Disorders and Global Disease Burden Implications
  JAMA Psychiatry, 2015
• Cardiovascular Risk Prediction Models for People With Severe Mental Illness
  JAMA Psychiatry, 2015
• Neural Correlates of Weight Gain With Olanzapine
  Archives of General Psychiatry, 2012
• Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
  World Psychiatry, 2011